Active substance
Tinzaparin
- SFDA 10
- US FDA 1
- Health Canada 11
- NHS prices 11
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| INNOHEP 10000 ANTI-XA IU-ML SYRING | 10000 IU/ml | Solution for injection · Subcutaneous use | 10 Pre-filled syringe | SAR 137.85 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 10000 ANTI-XA IU-ML SYRING | 10000 IU/ml | Solution for injection · Subcutaneous use | 10 Pre-filled syringe | SAR 177.05 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 10000 ANTI-XA IU-ML SYRING | 10000 IU/ml | Solution for injection · Subcutaneous use | 10 Pre-filled syringe | SAR 91.35 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 10000 ANTI-XA IU-ML VIAL | 10000 IU/ml | Solution · Subcutaneous use | 10 Vial | SAR 543.90 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 10000 ANTI-XA IU-ML VIAL | 10000 IU/ml | Solution · Subcutaneous use | 2 Vial | SAR 113.70 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 20000 ANTI-XA IU-ML SYRING | 20000 IU/ml | Solution for injection · Subcutaneous use | 2 Pre-filled syringe | SAR 100.60 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 20000 ANTI-XA IU-ML SYRING | 20000 IU/ml | Solution for injection · Subcutaneous use | 2 Pre-filled syringe | SAR 128.15 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 20000 ANTI-XA IU-ML SYRING | 20000 IU/ml | Solution for injection · Subcutaneous use | 2 Pre-filled syringe | SAR 81.25 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 20000 ANTI-XA IU-ML VIAL | 20000 IU/ml | Solution · Subcutaneous use | 1 Vial | SAR 113.70 | Biological · Prescription | Leo Pharma | Valid |
| INNOHEP 20000 ANTI-XA IU-ML VIAL | 20000 IU/ml | Solution · Subcutaneous use | 10 Vial | SAR 1087.75 | Biological · Prescription | Leo Pharma | Valid |
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; CARDIOMYOPATHY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); DIALYSIS; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HODGKIN'S LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS-ADVERSE REACTION MANAGEMENT; POLYCYTHEMIA VERA - THROMBOSIS; T-CELL LYMPHOMA-RENAL TOXICITY; VENOUS THROMBOEMBOLISM DISEASE (VTE)-PROPHYLAXIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INNOHEP | 20,000 IU/ML | injectable · injection | LEO PHARMA AS | Discontinued | 14 Jul 2000 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| INNOHEP | 02167840 | 10000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02229515 | 20000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02229755 | 10000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02231478 | 20000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02358158 | 10000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02358166 | 10000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02358174 | 20000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02358182 | 20000 UNIT / ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02429462 | 8000 UNIT / 0.4 ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02429470 | 12000 UNIT / 0.6 ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
| INNOHEP | 02429489 | 16000 UNIT / 0.8 ML | SOLUTION · SUBCUTANEOUS | LEO PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Tinzaparin sodium 10,000units/0.5ml solution for injection pre-filled syringes | £62.48 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 12,000units/0.6ml solution for injection pre-filled syringes | £74.97 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 14,000units/0.7ml solution for injection pre-filled syringes | £87.36 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 16,000units/0.8ml solution for injection pre-filled syringes | £99.96 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 18,000units/0.9ml solution for injection pre-filled syringes | £112.46 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 2,500units/0.25ml solution for injection pre-filled syringes | £21.29 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 20,000units/2ml solution for injection vials | £110.94 | 10 vial | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 3,500units/0.35ml solution for injection pre-filled syringes | £29.79 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 4,500units/0.45ml solution for injection pre-filled syringes | £38.30 | 10 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 40,000units/2ml solution for injection vials | £359.10 | 10 vial | 1 Oct 2026 |
| NHS Drug Tariff | Tinzaparin sodium 8,000units/0.4ml solution for injection pre-filled syringes | £49.98 | 10 pre-filled disposable injection | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.